Bolt Biotherapeutics Inc Ordinary Shares BOLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BOLT is a good fit for your portfolio.
News
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against NIKE, FutureFuel, SeaStar, and Bolt and Encourages Investors to Contact the Firm
-
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BOLT
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
-
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - BOLT
-
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Trading Information
- Previous Close Price
- $0.74
- Day Range
- $0.73–0.76
- 52-Week Range
- $0.71–1.56
- Bid/Ask
- $0.73 / $0.75
- Market Cap
- $28.60 Mil
- Volume/Avg
- 138,257 / 230,924
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.51
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 100
- Website
- https://www.boltbio.com
Comparables
Valuation
Metric
|
BOLT
|
LYEL
|
ITOS
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.27 | 0.69 | 1.14 |
Price/Sales | 2.51 | 6,074.07 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
BOLT
LYEL
ITOS
Financial Strength
Metric
|
BOLT
|
LYEL
|
ITOS
|
---|---|---|---|
Quick Ratio | 5.46 | 16.27 | 12.80 |
Current Ratio | 5.68 | 16.51 | 13.51 |
Interest Coverage | — | — | — |
Quick Ratio
BOLT
LYEL
ITOS
Profitability
Metric
|
BOLT
|
LYEL
|
ITOS
|
---|---|---|---|
Return on Assets (Normalized) | −30.85% | −21.31% | −16.56% |
Return on Equity (Normalized) | −41.85% | −24.24% | −18.86% |
Return on Invested Capital (Normalized) | −40.81% | −25.73% | −22.78% |
Return on Assets
BOLT
LYEL
ITOS
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Kwwtqqfl | Vhtf | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Ygtxxzwf | Tqfhks | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Gjhxbbjp | Bwtgg | $118.7 Bil | |||
Moderna Inc
MRNA
| Gtxdlnpn | Hqqf | $46.8 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Nchjjxkv | Tnbqs | $29.7 Bil | |||
argenx SE ADR
ARGX
| Vpsczsr | Pwb | $29.3 Bil | |||
BioNTech SE ADR
BNTX
| Rjzgltp | Wlwc | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Jnmhsbpk | Sgqkyxp | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Msxkmttf | Lryt | $15.0 Bil | |||
Incyte Corp
INCY
| Dktntldw | Czclq | $13.5 Bil |